Pearl River Capital’s Charles River Laboratories CRL Stock Holding History

Pearl River Capital’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,580	Closed	-$338K	–	467
2022 Q2	$338K	Buy	+1,580	New	+$386K	0.08%	333
2020 Q2	–	Sell	-1,748	Closed	-$221K	–	345
2020 Q1	$221K	Buy	1,748 +112	+7%	+$16.8K	0.43%	71
2019 Q4	$250K	Buy	+1,636	New	+$227K	0.09%	397
2019 Q3	–	Sell	-754	Closed	-$107K	–	440
2019 Q2	$107K	Sell	754 -114	-13%	-$15.5K	0.68%	65
2019 Q1	$126K	Buy	+868	New	+$114K	0.31%	152

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Pearl River Capital's CRL Position: Q3 2022 in Review

Pearl River Capital sold out of Charles River Laboratories (CRL) in Q3 2022, closing a stake of 1,580 shares — an estimated $338K sold.

Pearl River Capital first reported a position in CRL in Q1 2019 and held it in 5 quarters. The position peaked at $338K in Q2 2022. 583 funds tracked by Wall St. Rank hold CRL as of Q3 2022.

Pearl River Capital reported no remaining Charles River Laboratories position as of Q3 2022 after selling out during the quarter.
Pearl River Capital sold 1,580 Charles River Laboratories shares in Q3 2022, an estimated $338K.
Pearl River Capital first reported a position in Charles River Laboratories in Q1 2019 and held it in 5 quarters.
Pearl River Capital's Charles River Laboratories position peaked at $338K in Q2 2022.
583 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2022.

Based on Pearl River Capital's 13F filing for Q3 2022, filed 14 Nov 2022.